Female BRCA1/2 carriers have two preventive options regarding breast and ovarian cancer: a tailored surveillance program to detect potential breast and ovarian cancer as early as possible using radiological screening modalities and measurement with the biomarker CA-125 (for ovarian cancer) or surgical interventions with bilateral risk-reducing mastectomy (BRRM) and risk-reducing salpingo-oophorectomy (RR-BSO) [6]. The gene discussed is BRCA1; the disease is ovarian cancer.